> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Novartis Gains Approval of IV Cosentyx
- URL: https://www.fdaweb.com/novartis-gains-approval-of-iv-cosentyx/
- Published: 2023-10-06T12:00:00.000Z
- Updated: 2026-09-14T19:01:14.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155507

FDA has approved Novartis’ intravenous (IV) Cosentyx (secukinumab) formulation for treating adults with psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The non-tumor necrosis factor alpha IV formulation offers patients a monthly 30-minute, weight-based dosing option, requiring no pre-medication and no lab monitoring, the company says. Cosentyx targets and blocks interleukin-17A, an important cytokine involved in the inflammation of the indicated conditions. The drug was originally approved by FDA in 2015 for treating moderate-to-severe plaque psoriasis.